Trevi Therapeutics (TRVI) Total Debt (2020 - 2023)

Trevi Therapeutics' Total Debt history runs 4 years deep, the most recent figure standing at $7.5 million for Q1 2023.

• On a quarterly basis, Total Debt fell 46.77% year-over-year to $7.5 million in Q1 2023; TTM through Mar 2023 was $7.5 million, a 46.77% decrease from a year earlier, with the FY2022 full-year figure at $9.2 million, down 36.82% from the prior year.
• Total Debt fell to $7.5 million in Q1 2023 per TRVI's latest filing, from $9.2 million in the prior quarter.
• Across five years, Total Debt topped out at $14.5 million in Q4 2021 and bottomed at $7.5 million in Q1 2023.
• The 4-year median for Total Debt is $14.0 million (2020), against an average of $12.6 million.
• Across the five-year window, Total Debt advanced 3.84% in 2021 and sank 46.77% in 2023, its largest moves.
• Year by year, Total Debt stood at $14.0 million in 2020, then grew by 3.81% to $14.5 million in 2021, then slumped by 36.82% to $9.2 million in 2022, then declined by 18.24% to $7.5 million in 2023.
• Per Business Quant, the three latest TRVI Total Debt figures stand at $7.5 million (Q1 2023), $9.2 million (Q4 2022), and $10.8 million (Q3 2022).